Trial Profile
Retrospective study of use of 90Y-ibritumomab tiuxetan in low-grade B cell non-Hodgkin's lymphoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Dec 2015
Price :
$35
*
At a glance
- Drugs Ibritumomab tiuxetan (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions; Therapeutic Use
- 02 Dec 2015 New trial record